Učitavanje...
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
INTRODUCTION: Deciding on an optimal medication choice for type 2 diabetes is often challenging, due to the increasing number of treatment options. Canagliflozin is a novel glucose-lowering agent belonging to sodium–glucose co-transporter 2 (SGLT2) inhibitors. AIM: The aim of this study was to exami...
Spremljeno u:
| Izdano u: | Core Evid |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5358960/ https://ncbi.nlm.nih.gov/pubmed/28352212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S109654 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|